Table 3.
Follow-up status of participants at 180 days by randomization group, Group Health, Washington State 2010-2012
| OC-Auto® | InSure® | Hemoccult SENSA® | |
|---|---|---|---|
| N = 739 | N = 741 | N = 754 | |
| FOBTa, No. (%) | |||
| Completed assigned study FOBT | 473 (64.0%) | 445 (60.1%) | 403 (53.4%) |
| Completed non-study FOBT | 31 (4.2%) | 26 (3.5%) | 53 (7.0%) |
| Endoscopy, No. (%) | |||
| Colonoscopy | 13 (1.8%) | 18 (2.4%) | 18 (2.4%) |
| Flexible Sigmoidoscopy. | 2 (0.3%) | 2 (0.3%) | 0 (0%) |
| Still at risk for screening at 180 days | 203 (27.5%) | 236 (31.8%) | 260 (34.5%) |
| Withdrawal, No. (%) | |||
| Self-report ineligible | 1 (0.1%) | 0 (0%) | 0 (0%) |
| Self-report up to date | 4 (0.5%) | 1 (0.1%) | 5 (0.7%) |
| Request termination | 0 (0%) | 0 (0%) | 1 (0.1%) |
| Disenrolled from GH, No. (%) | 12 (1.6%) | 13 (1.8%) | 14 (1.9%) |
Abbreviations: FOBT, fecal occult blood test.
a
Percents do not exactly match those in Table 4, which were derived from a competing risks analysis which allowed the denominator to change over time based on who was still “at risk” of screening. This table uses a fixed denominator for each column (i.e., the number of participants eligible for analysis assigned to that group).